Navigation Links
Osteotech Reports 2008 Third Quarter Financial Results
Date:11/7/2008

s of $1.1 million related to the settlement of certain litigation.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "The transition of our business model is almost complete. Our new product development strategy is on track to deliver new biologic products to the marketplace. We continue to execute on our access distribution strategy and we built leverage into our back office structure and systems. I continue to be encouraged by the progress we are making. We are confident the new product introductions scheduled for 2009 and increased effectiveness of our distribution system will be the catalysts to allow us to continue the growth of our base line business."

Mr. Owusu-Akyaw will host a conference call on November 7, 2008 at 9:00 a.m. Eastern Time to discuss 2008 third quarter financial results. You are invited to listen to the conference call by dialing 1-973-200-3375. The conference will also be simultaneously webcast at http://www.osteotech.com. Automated playback will be available two hours after completion of the live call, through midnight, on Friday, November 21, 2008, by dialing 1-706-645-9291 and indicating access code 66480835.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
7. Osteotech to Present at the Sidoti Conference in New York
8. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
9. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
10. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
11. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... including DESY scientists has observed tiny quantum vortices in ... the journal Science that the exotic vortices ... It is the first time that the quantum vortices, ... what is known as superfluid helium, have been detected ... says Andrey Vilesov of the University of Southern California, ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2
... and LEXINGTON, Massachusetts, August 25, 2011 Shire ... specialty biopharmaceutical company, today announced that the U.S. Food and ... (icatibant injection) for treatment of acute attacks of hereditary ... "Until now, HAE patients faced challenges gaining rapid ...
... CBI, a division of Advanstar Communications, is pleased ... Tufts Center for the Study of Drug Development and ... the keynote speaker at their Pharma/Bio Forum on Preclinical ... at the Hyatt Harborside in Boston, MA. Dr. Kaitin ...
... school science teachers will explore the nanotechnology field at ... build interest in science and engineering. ... of Engineering a $429,000 grant to fund "Innovations in ... Starting next summer, selected middle and high school ...
Cached Biology Technology:FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 6Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference 2University of Houston receives NSF grant for high school teachers program 2
(Date:8/21/2014)... involves the pancreas digesting itself resulting in severe abdominal ... UK around 20,000 patients are diagnosed with the disease ... and treatment is restricted to intravenous fluid and nutritional ... of Life Sciences, who led the research, said "The ... gall stones and excessive alcohol intake combined with a ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... second most common cause of childhood blindness in the ... earlier than or at 28 weeks gestational age. The ... the retina of the eye. ROP risk increases with ... Brigham and Women,s Hospital (BWH) suggests that the antioxidant, ...
... young researchers were named Pew Scholars in the Biomedical ... join a prestigious community that includes Nobel Prize winners, ... Research Award. "During these challenging budgetary ... harder for scientists to obtain, we are proud to ...
... heavy rain, the lid of Nepenthes gracilis ... shelter on its underside directly into the fluid-filled pitcher, ... Wednesday 13 June, in the journal PLoS ONE ... a source of nutrients, enabling them to colonise nutrient-poor ...
Cached Biology News:Antioxidant shown to reduce blindness risk in extremely premature babies 222 of America's most promising scientists selected as Pew Biomedical Scholars 222 of America's most promising scientists selected as Pew Biomedical Scholars 3Pitcher plant uses rain drops to capture prey 2
... using many of the automation concepts from ... requirements are similar to those for HTS: ... 24 or 48 wells with well volumes ... the number of wells has increased to ...
... One-Step Kit is the ultimate in ... It has been specifically designed to ... Reverse-iT™ One-Step Kit combines the unique ... Thermoprime Plus DNA Polymerase to provide ...
... Immunogen: Synthetic Peptide: M(1) E F L ... P P T M D L E(19) PA1-072 ... cells.,PA1-072 has been successfully used in Western blot ... an ~86 kDa protein representing Mint3 from AtT20 ...
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
Biology Products: